New Covid-19 Vaccine Trial at Hoag Hospital Shows Promising Results
A Groundbreaking Covid-19 vaccine trial is underway at Hoag Memorial Hospital Presbyterian in Newport Beach, California, offering a novel approach to combating the virus. The trial, focusing on a vaccine developed by NantKwest Inc.and ImmunityBio, is unique in its dual-targeting mechanism, possibly providing more durable immunity.
First Volunteer Receives Pioneering covid-19 Vaccine
Chen Cao, A Uci Graduate, became the first of 35 volunteers to receive the experimental Covid-19 vaccine at Hoag Hospital. This phase 1 clinical trial aims to evaluate the vaccine’s safety and ability to stimulate an immune response. Hoag Memorial Hospital Presbyterian is the exclusive location for this trial.
Dual-Action Vaccine Targets Spike Protein and Nucleocapsids
Most Covid-19 vaccines target the spike protein on the coronavirus, which gives it its “corona” or crown-like appearance. The NantKwest/ImmunityBio vaccine, however, goes a step further. It targets not only the spike protein but also structures within the virus’s cytoplasm called nucleocapsids. Targeting nucleocapsids has been shown to stimulate T-cell responses,which are crucial for long-lasting immunity.
Philip Robinson, Hoag’s Medical Director Of Infection Prevention And Principal Investigator For The Vaccine Trial, emphasized the importance of T-cell response, stating, “This vaccine is novel because it stimulates the second arm of the immune system, the cell-mediated immunity, the T-cell response.”
Why T-Cell Immunity Matters
T-cell responses are believed to offer more durable protection compared to antibody responses generated by targeting the spike protein alone. Studies on Sars-Cov 1, a related virus, showed that patients who developed T-cell immunity maintained it for as long as 17 years post-infection. this suggests that a vaccine inducing strong T-cell responses could provide longer-term protection against Covid-19, a crucial advantage as new variants emerge.
Did you know? Recent studies suggest that hybrid immunity from vaccination and prior infection offers the strongest protection against current Covid-19 variants.
Advantages of the NantKwest/ImmunityBio Vaccine
The vaccine’s dual-targeting approach could prove favorable in the face of emerging mutations in the spike protein, which might reduce the effectiveness of vaccines targeting only the spike protein. Additionally, this vaccine has several other promising features:
- Uses an adenovirus vector modified to be “invisible” to the body’s immune system, reducing the risk of it being attacked before it can deliver its payload.
- Requires only standard refrigeration, avoiding the logistical challenges associated with vaccines that need ultra-cold storage.
- Potentially deliverable via oral or nasal spray, simplifying administration.
| Vaccine Feature | NantKwest/immunitybio | Typical Spike-Only Vaccines |
|---|---|---|
| Target | Spike Protein & Nucleocapsids | Spike protein Only |
| Immune Response | T-Cell & Antibody | Primarily Antibody |
| Storage | Standard Refrigeration | May Require Ultra-Cold |
| Delivery | Injection, Potential Oral/Nasal | Injection |
Trial Progress and Future Plans
Five volunteers received their first injections last week, with five more scheduled for this week. Following each set of 10 injections, the trial will pause for safety reviews and assessment of immune system reactions. If phase 1 proves accomplished, the trial will expand into phases 2 and 3 next year, involving hundreds and then thousands of participants.
Hoag Hospital has extensive experience in Covid-19 clinical trials, having participated in over 20 since the start of the pandemic. Hoag Hospital is the only orange County hospital and the only nonacademic institution to offer the companies’ phase 2 immunotherapy clinical trial for solid tumors.
Chen Cao, as the first participant, is closely monitored for any side effects, maintaining a diary and undergoing regular evaluations and blood draws. Interested individuals can contact [email protected] to learn more about participating.
The Future of Covid-19 Vaccines
As the Sars-Cov-2 virus continues to evolve, the advancement of more effective and adaptable vaccines remains a critical priority.The dual-targeting approach employed by the NantKwest/ImmunityBio vaccine represents a promising avenue for enhancing the durability and breadth of protection against Covid-19 and its emerging variants. Furthermore, innovations in vaccine delivery methods, such as oral or nasal sprays, could substantially improve accessibility and ease of administration, particularly in resource-limited settings.
Pro Tip: stay informed about approved Covid-19 vaccines and boosters recommended by health authorities like the Cdc and Who to optimize your protection.
The Ongoing Research Into Coronaviruses and the Immune System Is Paving The Way For Next-generation Vaccines That Offer Broader And More Durable Immunity. Such Advancements Are Essential For Sustained Control Of The Pandemic And Mitigation Of Future Outbreaks.
Frequently Asked Questions About covid-19 Vaccines
-
What Makes This Covid-19 Vaccine Trial At Hoag hospital Unique?
The Covid-19 Vaccine Trial At Hoag Hospital Is Unique Because It Targets Both The Spike Protein And The Nucleocapsids Of The Virus, Potentially Leading To A More Durable Immune Response.
-
How Does Targeting T-Cells Improve The Effectiveness Of A Covid-19 vaccine?
Targeting T-Cells Can Improve The Effectiveness Of A Covid-19 Vaccine By Providing Longer-Lasting Immunity Compared To Vaccines That Only Stimulate Antibody Responses.
-
What Are The Advantages Of Standard Refrigeration For A Covid-19 Vaccine?
Standard Refrigeration For A Covid-19 Vaccine Simplifies Storage And Distribution, Making The Vaccine More Accessible, Especially In Areas With Limited Resources.
-
How Many Covid-19 Vaccine Candidates Are Currently In Clinical Evaluation Worldwide?
according To The World Health Organization, There Are Currently 44 Covid-19 Vaccine Candidates In Clinical Evaluation Worldwide.
-
What Should I Do If I’M Interested In Participating In Future Covid-19 Vaccine Trials at Hoag?
If you Are Interested In Participating In Future Covid-19 Vaccine Trials At Hoag, You Can Email [email protected] For More Information.
what are your thoughts on this new approach to Covid-19 vaccines? Do you think targeting T-cells will provide longer-lasting immunity? Share your comments below!
Disclaimer: This article provides information about a clinical trial and should not be considered medical advice. Consult with a healthcare professional for any health concerns.
